Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
Reena Khanna(University of Toronto), Brian G. Feagan(Western University), Thomas D. Walters(University of Toronto), Waqqas Afif, Richard N. Fedorak(University of Alberta), John K. Marshall(McMaster University), Alain Bitton(McGill University Health Centre), William J. Sandborn(University of San Diego), Ernest G. Seidman(Université de Montréal), Richmond Sy, Eric I. Benchimol(University of Toronto), Bernie D. Sattin, Gert Van Assche(KU Leuven), Brian Bressler(University of British Columbia), A. Hillary Steinhart(Mount Sinai Hospital), Subrata Ghosh(University College Cork), Gordon R. Greenberg(University of Toronto), Mark S. Silverberg(Sinai Health System), Edmond Jean Bernard(Centre Hospitalier de l’Université de Montréal), Remo Panaccione(University of Calgary)
Cited by 106
Related Papers
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
|PLoS Medicine|2015|5.2k
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k